Europe Plasma Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By End User, By Product Type (Immunoglobulin, Albumin, Plasma derived factor VIII, and Others), By Application, By Country and Growth Forecast, 2023-2029

The Europe Plasma Protein Therapeutics Market should witness market growth of 5.1% CAGR during the forecast period (2023-2029).

Plasma fractionation has changed from a mostly local community-focused medical care activity to a manufacturing sector that complies with strict regulatory requirements. These stringent criteria begin with the plasma collection for fractionation and extend to the production and distribution of products.

Proteins that are lacking or insufficient are replaced by plasma-derived therapies, enabling patients to live healthier, more productive lives. Most patients who depend on these treatments need ongoing infusions or injections. Plasma protein treatments are used to treat rare diseases and ailments, most of which are inherited, chronic conditions that only impact a small percentage of the population.

The plasma-derived therapies business helps to sustain the European economy. The industry's manufacture of plasma-derived medicines is directly impacted by economics. Subcontractors to the blood plasma-derived therapies sector, such as those at plasma collection facilities, cleaning businesses, or IT solution providers, are responsible for the indirect consequences. Induced effects are the value produced for industry workers and subcontractors. In order to grasp the magnitude, figures for these impacts have also been generated. The direct effects alone may exceed three billion euros, and the indirect and induced effects may roughly triple the total economic contribution. Therefore, the region presents lucrative growth opportunities for market advancement.

The Germany market dominated the Europe Plasma Protein Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,565.8 Million by 2029. The UK market is anticipated to grow at a CAGR of 4.2% during (2023-2029). Additionally, The France market would exhibit a CAGR of 5.9% during (2023-2029).

Based on End-user, the market is segmented into Hospitals, and Others. Based on Product Type, the market is segmented into Immunoglobulin, Albumin, Plasma derived factor VIII, and Others. Based on Application, the market is segmented into Hemophilia, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Abeona Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Grifols, S.A., Baxter International, Inc., Kedrion S.p. A, Octapharma AG, CSL Limited (CSL Behring), Taibang Biological Group Co., Ltd and ADMA Biologics, Inc.

Scope of the Study

By End-user

• Hospitals
• Others

By Product Type

• Immunoglobulin
• Albumin
• Plasma derived factor VIII
• Others

By Application

• Hemophilia
• Idiopathic Thrombocytopenic Purpura
• Primary Immunodeficiency Disorder
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Bayer AG
• Abeona Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Baxter International, Inc.
• Kedrion S.p. A
• Octapharma AG
• CSL Limited (CSL Behring)
• Taibang Biological Group Co., Ltd
• ADMA Biologics, Inc.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free